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1. Abstract 
The relationship between the clinical features of dementia disorders and the resultant 
changes in underlying neuropathological mechanisms has long been of interest to 
researchers working in the field of neurodegenerative disorders. The majority of 
neuropathological research in dementia has utilized semi-quantitative analysis of 
protein inclusions, which have defined the hallmark histological features of the 
conditions. However, the advent of three-dimensional stereological techniques has 
enabled unbiased and fully quantitative assessment of brain tissue. The present 
review focuses on studies that have used these techniques to elucidate important 
relationships between neuropathological changes and clinical features and, in doing 
so, revealed important mechanistic insights into the pathophysiology of dementia 
disorders.   
 
2. Introduction 
Understanding the neuropathological correlates of the neurodegenerative dementias 
has remained a subject of intense interest and scrutiny over many decades. 
Neurodegenerative processes involve cascades of pathological events that culminate 
in the progressive and irreversible dysfunction and destruction of neurons and 
synapses, spreading in a stereotypical fashion through regions of the brain, defining 
its clinical presentation (Jellinger, 2001, Jellinger, 2012). The spectrum of dementing 
neurodegenerative disorders are usually bound by a common pathological factor, 
namely the presence of aberrant misfolded intra- and extra-cellular deposits of native 
proteins (Hardy and Gwinn-Hardy, 1998, Hyttinen et al., 2014). The neuron 
populations and brain areas affected are generally defined by the protagonist protein, 
thus characterizing clinical symptomatology (Taipa et al., 2012).  
In large, the findings that have defined the major neuropathological markers 
associated with neurodegenerative dementias have stemmed from semi-quantitative 
‘two-dimensional’ methods. Indeed, all major staging criteria in neurodegenerative 
dementias recommend single section sampling of markers in specific anatomical 
regions deemed vulnerable to pathological changes in the brain and brainstem (Braak 
and Braak, 1995, Montine et al., 2012, Thal et al., 2002, Braak et al., 2004, McKeith 
et al., 2005). Whilst this method is widely used the classification of diseases in post-
mortem tissue, this approach is undermined by factors arising from bias in the 
interpretation of three-dimensional structures and markers on two-dimensional 
sections taken from one part of a particular reference area. Stereological analysis, on 
the other hand, describes a methodological approach that provides a three-
dimensional interpretation of structures based on observations made on two-
dimensional sections, representing the ‘gold standard’ for the unbiased assessment 
of the structural components of the brain. This means that the strict sampling protocol 
that stereology requires is often at odds with the need for the rapid and efficient 
classification of cases, where a balance must be met between diagnostic and research 
requirements.    
Despite the difficulties in incorporating stereological protocol into analysis of 
pathological changes, the inherent benefits of the approach have encouraged 
researchers to seek out the often subtle changes to the human brain across the 
various dementing disorders. This review draws together a plethora of diverse 
stereological studies that have mapped morphological changes in the brain, such as 
in neuronal populations or vascular integrity, with ante-mortem clinical and/or post-
mortem pathological correlates.  
 
3. The benefits of stereological analysis in post-mortem human brain tissue 
analysis 
 
The problems arising from two-dimensional analysis, including issues surrounding the 
‘reducing fraction’, widely used ‘correction’ formulae, such as that devised by 
Abercrombie, and the ‘reference trap’, arising from the use of density as a proxy 
measure of number, have been well documented elsewhere (Clarke, 1992, Hedreen, 
1998) and beyond the scope of this review. However, despite the inherent difficulties 
in conducting three-dimensional analysis in post-mortem human brain tissue, well-
designed and executed stereological studies have been performed. The findings 
emanating from such studies have yielded novel, interesting and, importantly, 
accurate, findings in field of dementia research.  
 A properly conducted design-based stereological study should be free of 
methodological ambiguity, requiring meticulous planning and preparation prior to 
commencing any experiment. Firstly, a clearly defined reference volume (Vref) should 
be defined for sampling in its entirety. The entire reference space can be 
systematically uniformly randomly sampled in the z-axis within serially sectioned 
structures or from blocks of tissue of a defined thickness. In the case of larger 
structures, such as neocortical regions, blocks of tissue may be acquired and sections 
taken at precisely defined intervals (e.g. 5mm to 1cm) (Fabricius et al., 2013, Pelvig 
et al., 2008). For smaller structures, such as brain nuclei or glands, serial sectioning 
may be more appropriate. In both cases, a uniform, random starting point should be 
selected within the first interval, followed by a complete series of sections at equally 
spaced intervals through the entire Vref. Uniform, systematic sampling should also be 
applied to the Vref on sections in the x and y axes, through the use of a probe relevant 
to the parameter measured of a specific size and depth, placed randomly and 
uniformly through the entire reference space at intervals, reflecting the desired level 
of accuracy of the population estimate from taking coefficient of error (CE) levels into 
account. The Vref may be calculated using Cavalieri’s formula:    
V = T · a(p) · ∑ P, 
where T is the slab thickness or intersectional distance, a(p) is the area per point, and 
∑ P is the sum of points hitting the reference area.  
Using the Vref, calculated from Cavalieri’s formula, one may then estimate the total 
number, length or surface area of objects per Vref using a suitable probe. Most of the 
studies included in this review have used the optical disector approach (Gundersen et 
al., 1988) for the calculation of total neuron number, which uses the following formula: 
𝑁𝑣 =
∑ 𝑄−𝑝−
𝑃 ⋅ 𝑉
 
where 𝑁𝑣 is the numerical density,  𝑝 − is the disector samples, 𝑄− is the Q-weighted 
number of objects counted, 𝑃 is the total number of disectors, and 𝑉 is the disector 
volume. 
A number of studies reviewed have also employed the physical disector (Sterio, 1984) 
approach to calculate synapse (Scheff et al., 2013, Scheff et al., 2011) and neuron 
(Pakkenberg et al., 1991) number. Here, pairs of thin sections are taken at intervals 
through the Vref and the objects observable in the first, but not second, section of the 
pair are counted. This approach is useful when objects are large relative to section 
thickness, lending itself particularly well to images acquired from electron microscopy 
(Scheff et al., 2013, Scheff et al., 2011).    
Alternatively, some studies reviewed (Joelving et al., 2006, Piguet et al., 2011) have 
employed the optical fractionator (Gundersen et al., 1988). Here, the total number of 
objects can be calculated by combining the optical disector with a systematic uniform 
sampling scheme, the fractionator. The optical fractionator estimates the total number 
of particles (N) of the Vref obtained by multiplying the reciprocals of the fractions with 
the total particle count (ΣQ−) per brain structure obtained within the optical disectors:  
N = ssf-1 · asf-1 · tsf-1 · ∑Q-1, 
where ssf is the section sampling fraction, asf is the sampling fraction, tsf is the 
thickness sampling fraction and ∑Q- is the total number of objects counted within the 
disector.  
As most post-mortem tissue is cut in a non-random fashion in a vertical, uniform 
random manner, length and surface area measures could potentially be biased as a 
result of their orientation in the brain. For example, in the measurement of neuronal 
white matter tracts, the relationship between probe and the structure may be highly 
anisotropic, leading to inaccurate estimates of length. As such, reviewed studies 
examining the length of structures, e.g. neuropil threads (Giannakopoulos et al., 2007) 
have employed an intrinsically isotropic probes such as the cycloid or spherical ‘space 
ball’ (Mouton et al., 2002) probes.   
 4. Alzheimer’s disease 
Alzheimer’s disease (AD) is the most prevalent form of age-related dementia, 
accounting for approximately 70% of cases (Reitz and Mayeux, 2014). Clinically, AD 
is marked by memory loss and impaired reasoning with a gradual onset and a 
progressive course (McKhann et al., 2011). Neurofibrillary tangles of phosphorylated 
tau protein within neurons and extracellular plaques consisting of amyloid-β protein 
are considered to be the characteristic neuropathological findings in AD upon post-
mortem histological examination (Montine et al., 2012). Neurofibrillary tangles and 
amyloid-β plaques are encountered at pathological predilection sites at early and pre-
symptomatic stages, prior to stereotypical sequences of accumulation and deposition 
in vulnerable brain regions (Stratmann et al., 2015)  
The hallmark pathological lesions in AD are also typically found in the elderly non-
demented (Tomlinson et al., 1968, Price et al., 2009, von Gunten et al., 2010, 
Schneider et al., 2009), which has prompted speculation that AD is linked to senescent 
mechanisms in the brain (Herrup, 2010, Yankner et al., 2008). To investigate the link 
between senescence and AD, stereological studies have evaluated patterns of 
neuronal loss with aging in the absence of dementing symptoms, and compared these 
findings to neuronal loss typically observed in AD. West et al (1994) used the point 
counting method and optical disector probe to estimate neuronal number in subregions 
of the hippocampal formation and found age-related reductions in neurons in the CA4 
and subiculum in controls ranging from 13 to 101 years. However, CA1 neuronal loss 
was found to be distinct to AD cases and not found in normal aging cases, suggesting 
specific patterns of neuronal loss in AD and that progressive aging alone cannot fully 
explain the pathological changes of AD (West et al., 1994).  
Several staging schemes have illustrated the pathological progression of the 
characteristic lesions of AD (Braak et al., 2006, Thal et al., 2002, Josephs et al., 2014). 
Stereological designs have been used to study sites that are affected at early stages 
of the pathological process, often by comparing cases that had different levels of 
cognitive ability prior to death. These studies have often benefitted from excellent 
clinical information that can be compared to any observed cytoarchitectonic changes 
that may occur in tandem with cognitive dysfunction. However, some degree of caution 
must be exercised when comparing clinical information obtained during life with post-
mortem findings. AD is marked by progressive deterioration meaning that control of 
the interval between the last clinical assessment and death is of great importance.  
Assessment of whole brain hemispheres at systematic intervals from slabs using 
region point counting with the Cavalieri principle to determine volume of the neocortex 
and central grey matter (basal ganglia, thalamus, hypothalamus and substantia 
innominata) has shown volumetric reductions in the neocortex in AD cases when 
analysed as a whole. Parcellation into individual lobes showed significant reductions 
in the occipital lobe only (Regeur, 2000). However, when the cohort was stratified 
based on severity of cognitive dysfunction, neocortical and subcortical grey matter 
structures decreased in volume with progressive clinical severity. Shrinkage following 
fixation in formaldehyde has long been known exist in post-mortem brain tissue 
(Mouritzen Dam, 1979). This study did not note the exact fixation period, beyond being 
greater than five months, thus introducing the possibility of fixation-related bias 
A more region-specific approach has been used to investigate pathological 
predilection sites, such as the CA1 sector of the hippocampus and layer 2 of the 
entorhinal cortex, which are both affected at early stages of the pathological 
progression of AD (Thal et al., 2002, Braak et al., 2006). Post-mortem assessment of 
these regions was compared with the clinical dementia rating scale (CDR) to assess 
structural changes related to clinical phenotype (von Gunten et al., 2006). The entire 
hippocampus was sampled coronally by cutting into slabs along the anterior-posterior 
extent of the hippocampus. Sections were acquired from each slab at intervals and 
volume estimated using Cavalieri’s method. Using the optical disector, a loss of 
neurons was found in the CA1, even at the earliest evidence of cognitive decline on 
the CDR, and that this progresses linearly with increasing cognitive decline. The 
entorhinal cortex showed a similar pattern, though a more marked loss of neurons was 
found in CDR level 1 (the lowest level of impairment). Regression models for the 
quantitative measures of neuropathological lesions in these regions showed that 
neurofibrillary tangles, but not amyloid-β, significantly predicted the loss in neuron 
numbers. However, neurofibrillary pathology only partially predicted the degree of 
neuron loss in these models, leading the authors to speculate that more downstream 
mechanisms are also responsible for the degeneration observed.    
Another stereological study of the entorhinal cortex also aimed to investigate the early 
process of neurodegeneration in AD (Gomez-Isla et al., 1996a) by assessing 
differences in neuronal number between progressively aged control cases and cases 
at various stages of cognitive impairment, based on CDR scores. To sample the entire 
entorhinal cortex, the structure was serially sectioned before taking five sections from 
a random starting point, with a 3 mm interval between each. Volume was determined 
using Cavalieri’s method and neuronal density was estimated used the optical 
disector. Increasing age was not found to be related to any changes in number or 
density of neurons or the total volume of the entorhinal cortex. However, neuronal loss 
was found in all layers in AD, when compared to controls, but was especially severe 
in layer 2, with cases at the mildest stages of cognitive impairment showing significant 
loss in layers 2 and 4. The authors suggest that the dramatic loss at the earliest stages 
of cognitive decline, with no losses as a result of age, provide evidence for AD being 
a disease entity that is separate from an acceleration of the process of aging.  When 
assessing findings from the entorhinal cortex, it should be noted that the cellular 
populations of the entorhinal cortex are highly variable across cases both with and 
without neurological disease (Heinsen et al., 1996). This is especially important as the 
number of cases used at certain levels was low, with only two CDR1 cases used in 
the former study.       
As mentioned earlier, stereological methods have applications beyond ascertainment 
of the number of neurons per structure, and can be used to determine the number or 
size of neuropathological lesions within brain regions of interest. This approach has 
been used in the investigation of the hippocampal formation and the superior temporal 
gyrus, regions known to be vulnerable to AD pathology at early stages of disease 
(Braak et al., 2006). Studies in the superior temporal gyrus have conducted analyses 
of pathology burden (Gomez-Isla et al., 1996b) and neuronal number (Gomez-Isla et 
al., 1997). These studies have both obtained the volume of structures using Cavalieri’s 
method and combined this with the density of either pathological lesions or neurons 
using a subsample of the cortex being assessed. These studies revealed correlations 
the now well established relationship between amyloid-β burden and apolipoprotein 
ε4 allele, as opposed to tau (Rigaud et al., 1999). Counts of neurofibrillary tangles 
have been compared with neuronal number estimates on adjacent sections of the 
superior temporal gyrus as well as the duration of illness (Gomez-Isla et al., 1997). 
However, the study also revealed a greater loss in neuron number than neurofibrillary 
tangles, suggesting clearance or only a small contribution of the protein to neuronal 
loss in AD (Gomez-Isla et al., 1997). Giannakopoulos et al  (2007) employed a similar 
approach by uniformly, randomly sampling the entire hippocampal-entorhinal region 
and estimating the total number of neurons within the CA1 sector of the hippocampus 
and entorhinal cortex, and compared this to the number of neurons bearing 
neurofibrillary tangles, the number and volume of amyloid-β plaques, and the length 
of neuropil threads using the cycloid probe (Giannakopoulos et al., 2007). This study 
found that amyloid-β was not related to neuron number in either region but that 
neurofibrillary tangle number was negatively correlated with neuron number in the CA1 
region. Neuronal losses in CA1 and the entorhinal cortex both correlated with CDR 
scores, as did neurofibrillary tangle number. Neuropil thread length was related to 
increasing CDR scores, but this effect was only mediated through their relationship to 
neurofibrillary tangles (Giannakopoulos et al., 2007).   
Mild cognitive impairment (MCI) is considered to be an intermediate state between 
normal levels of cognition and AD (Morris and Cummings, 2005) and provides a useful 
group for inclusion in studies that wish to assess changes that occur at early stages 
of cognitive decline. The degeneration of the cholinergic system in AD, including the 
nucleus basalis of Meynert (NBM), has been postulated to be an important pathogenic 
event in the development of the intellectual decline that marks AD (Perry et al., 1977). 
Mufson et al, 2000 investigated whether a loss of neurons expressing trkA receptors 
may underlie NBM degeneration in AD, due to the role of trkA receptors in maintaining 
the viability of these neurons (Mufson et al., 2000). The NBM from one hemisphere 
from AD, MCI and control cases was serially sectioned into 18 series to determine the 
volume of the NBM using the Cavalieri method and total number of trkA 
immunoreactive neurons calculated by the optical disector. A significant decrease in 
neurons expressing trkA receptors was found in AD and MCI cases, thus suggesting 
a reduction in trkA positive neurons in the NBM does not mark a transition from MCI 
to AD, as the MCI cases also showed reductions in neurons expressing trkA receptors 
(Mufson et al., 2000).  
Studies examining sites affected early in the pathological process of AD have also 
used MCI cases to compare the clinical time-point at which such sites become affected 
by neuropathological change. Kordower et al (2001) estimated the neuron number in 
individual layers of the entorhinal cortex using the Cavalieri and optical disector 
approach. Neuronal loss and neuronal volumetric reduction was found in layer 2 of the 
entorhinal cortex in AD and MCI cases. No difference was found in neuron number 
between AD and MCI, suggesting that loss or reduction in the size of neurons in layer 
2 of the entorhinal cortex does not underlie the transition from MCI to AD. However, 
loss of layer 2 volume was found between control and MCI, as well as MCI and AD, 
and such losses correlated with clinical measures of cognitive dysfunction obtained 
during life (Kordower et al., 2001).  
The posterior cingulate gyrus is affected at an early stage in the progression of AD 
and its degeneration may predict cognitive decline on neuroimaging (Barnes et al., 
2007, Johnson et al., 1998).  Based on previous findings showing that synaptic 
pathology is an early event in AD, and correlates well the onset with cognitive decline 
(Scheff and Price, 2006), Scheff et al, 2015 investigated synapse number in the 
posterior cingulate gyrus in AD, MCI and controls. Electron microscopy was used to 
determine synapse number within the posterior cingulate gyrus using the physical 
disector on randomly determined sections containing a superimposed counting frame 
on the micrograph (Scheff et al., 2015). A reduction in total number of synapses was 
found in AD patients, compared to control cases, with MCI cases showing no 
significant differences from AD or control cases. Total synapse number also 
significantly correlated with MMSE score, suggesting that synaptic dysfunction is an 
early event in cognitive impairment in AD.    
The precuneus is also affected by amyloid-β pathology at early stages of AD (Rowe 
et al., 2007). Scheff et al (2013) thus employed the physical disector to examine the 
number of synapses in this region. Alternate slabs of the precuneus gyrus were serially 
sectioned and sections systematically randomly uniformly sampled from within slabs. 
The remaining slabs were then used for pathological analyses (Scheff et al., 2013). 
Synaptic density was determined by sampling random areas within layer 3 of the 
precuneus using electron microscopy. The total number of synapses in layer 3 were 
reduced in AD cases. However, these reductions did not relate to any change in 
cognitive function or to the degree of amyloid-β burden in the precuneus. A related 
study (Scheff et al., 2011) using similar methodology but conducted in layer 3 of the 
inferior temporal gyrus showed showed significant reductions in synapse number in 
both AD and MCI when compared to controls, but no difference between AD and MCI. 
Volumetric measures of layer 3 of the inferior temporal gyrus suggested that AD and 
MCI were significantly reduced when compared to controls but that AD cases were 
also significantly reduced compared to MCI.     
An alternative approach in the elucidation of the temporal sequence of morphometric 
changes under neurodegenerative conditions is to use cases with varying degrees of 
neuropathological burden. Such an approach relies on the current staging schemes to 
accurately reflect the cognitive status of the individual and there is good evidence that 
they are good general indicators of cognition (Maderna et al., 2015, Price et al., 2009), 
with notable exceptions in the relationship between pathology and clinical phenotype 
(Gertz et al., 1998). Such studies, however, are particularly useful in identifying 
relationships between the spread of pathological lesions to different regions and the 
corresponding effects on cellular populations. One study employing this approach 
assessed the CA1 and subiculum in cases of varying degrees of global 
neuropathological burden, with the aim of identifying the stages at which cellular 
changes become prominent (Rossler et al., 2002). Region point counting using the 
Cavalieri method was used to estimate the volume and neuron number in subregions 
of the hippocampus. A loss of neurons in the CA1 region was found in Braak 
neurofibrillary stages 4 and 5, but not in Braak stages 1-3, or as a result of progressive 
age. There was a trend toward neuron loss in the subiculum in cases with Braak stage 
5 pathology, when compared against cases at Braak stage 1. The authors suggested 
that this study provides evidence for neuron loss in a region- and AD pathology stage-
specific manner.  
A combination of pathological and clinical data has also been used to identify cases 
possessing significant pathological burden, but no clinical history of dementia. As 
mentioned earlier, the hippocampus shows a pattern of neuron loss that is specific to 
AD, specifically in the CA1 sector (West et al., 1994), occurring in higher levels of 
global neurofibrillary pathology burden (Rossler et al., 2002). An investigation 
comparing control and AD cases to ‘preclinical AD’ cases with high global pathologic 
burden, but no clinical history of dementia in subdissected and systematically sampled 
hippocampus reported no difference in neuron  number in preclinical AD cases when 
compared against controls in any subregion of the hippocampus (West et al., 2004). 
This implies that neuronal loss in such regions may be related to the transition of the 
clinical threshold in AD. However, it should be noted that this study used ‘preclinical 
AD’ cases that were generally of intermediate AD pathologic change, ranging from 
Braak neurofibrillary pathology stages 2 to 4. As previously noted, changes have only 
previously been identified in Braak stages 4 and 5 in some of the regions measured 
(Rossler et al., 2002). Therefore, the inclusion of several cases with a Braak stage 
lower than 4 may have increased the variation in results and diminished the power of 
the study to identify a significant difference between ‘preclinical AD’ and AD.   
Neuroinflammatory responses mediated through glia are thought to play a prominent 
role in the etiology of AD, meaning glia may represent a useful target in the 
investigation of changes resulting from AD-type pathology (Heneka et al., 2015). 
Pelvig et al (2003) conducted morphometric assessment of glia, as well as neurons, 
from the entire cortical hemisphere, taking sections from the front of alternate slabs 
from a random starting point (Pelvig et al., 2003). Cavalieri’s method was used to 
determine grey and white matter volumes, whilst the optical disector was employed to 
estimate neuronal and glial density. This study found that AD cases had no significant 
differences in terms of neuronal or glial number compared to controls. The total 
neocortical and temporal lobe volume was, however, significantly reduced in AD 
cases.    
Cerebral white matter lesions are considered to be a risk factor for dementia. In the 
neocortex, stereological studies have shown a decrease in white matter volume by as 
much as 28% with progressive age (Pakkenberg and Gundersen, 1997). However, in 
AD, the volume of the white matter was found to be unchanged (Pelvig et al., 2003). 
Nevertheless, it has been suggested white matter changes may contribute to cognitive 
impairment in the elderly by slowing synaptic communication (Filley and Cullum, 
1994). On this basis, one study assessed myelinated fiber length and the mean 
diameter and volume density of white matter fibers (Jorgensen et al., 2008) using 
needle biopsies taken from tissue after a point grid was placed on the tissue to 
estimate fiber length, volume and number. Biopsies were randomly orientated and 
sectioned and the number of profiles per unit area was determined using disector 
counting frames. AD cases did not differ from controls in any parameters tested 
(Jorgensen et al., 2008).  
 
5. Parkinson’s disease and dementia with Lewy bodies 
Parkinson’s disease (PD) is a common neurodegenerative disorder, occurring in 
approximately 1% of people over the age of 60, but increasing in prevalence with 
advancing age (de Lau and Breteler, 2006). PD is primarily a motor disorder that is 
characterized by rigidity, bradykinesia, unstable gait and resting tremor (Mutch et al., 
1986). However, 24-31% of cases diagnosed with PD also have dementia (PDD) 
(Aarsland et al., 2005). PDD is marked by impairments to attention, memory, 
visuospatial function and executive faculties (Vasconcellos and Pereira, 2015). 
Dementia with Lewy bodies (DLB) is thought to be second most common form of 
degenerative dementia after AD, accounting for approximately 20% of dementia cases 
at autopsy (McKeith, 2000). Clinically, DLB manifests as a progressive decline in 
cognitive ability, with three core features of cognitive fluctuations, parkinsonism and 
visual hallucinations being considered characteristic features of the disorder (McKeith 
et al., 2005). PD/PDD and DLB are both pathologically characterized by the presence 
of ubiquitinated intracellular inclusions of aggregated α-synuclein known as Lewy 
bodies (Spillantini et al., 1997). Like proteinaceous inclusions seen in disorders such 
as AD, the sequence of Lewy body pathologic spread has been characterized in these 
disorders to standardize neuropathological assessment (McKeith, 2006, Braak et al., 
2004). 
The clinical features of PD and DLB differ somewhat from those observed in AD. Whilst 
AD is typically marked by a progressive impairment in memory, this is not as clinically 
prominent in PD and DLB (McKeith et al., 1996). Therefore, one important avenue in 
PD/DLB research has been to investigate whether changes to the hippocampus, a 
structure involved in memory and consistently implicated in the pathophysiology of AD, 
are also found in PD and DLB. To investigate the hippocampus in DLB and PD 
compared to control cases, one study sampled the rostrocaudal extent of the 
hippocampus using coronal tissue slabs taken at uniform intervals (Harding et al., 
2002). Volume and neuron measurements were conducted within the subdivisions of 
the hippocampus. A significant reduction in hippocampal volume was found in DLB 
cases, with specific atrophy present within the subiculum. Significant neuronal loss 
was only found in the subiculum of DLB cases, and PD cases showed no difference 
from controls in any parameter. Likewise, Joelving et al (2006) used the optical 
fractionator to estimate neuronal number in the hippocampi of mostly cognitively 
impaired PD cases of during life against control cases. The hippocampus was 
subdissected from serial uniform coronal slices of the entire hemisphere and sections 
systematically, randomly sampled from the front of each block. No significant 
difference in neuronal or glial cell number, or grey matter volume, was found in any 
region analysed. The authors suggested the findings provided evidence of a degree 
of specificity regarding topography of sites affected by neurodegenerative changes in 
dementia disorders and that hippocampal degeneration is not invariant across the 
spectrum of neurodegenerative dementia disorders. 
Neuroimaging studies of PD brains have previously shown cortical atrophy, suggesting 
cortical changes contribute to the manifestation of cognitive symptoms within this 
disorder (Becker et al., 1979). Additionally, PD brains typically show cortical 
involvement at the most severe stages of Lewy body pathology (Braak et al., 2004). 
Pedersen et al, 2005 used stereological methodology to investigate whether such 
changes to the cortex in PD were related to the number of neurons within the cortex 
(Pedersen et al., 2005). No change in total neuronal number or volume was found in 
in PD cases in the neocortex. Furthermore an increase in neuron number was found 
in the temporal lobe of PD cases. This study thus implies that the volumetric reductions 
and Lewy body pathology previously reported in the cortex in imaging studies do not 
translate to changes to cortical neuron populations that PD cases. 
The motor symptoms that characterize PD are thought to result from the degeneration 
of pigmented dopamine-producing neurons of the midbrain structure, the substantia 
nigra (Mettler, 1964). Stereological studies have thus examined absolute neuronal 
numbers in PD cases. To investigate the degree of nigral neuronal loss in PD, 
Pakkenberg et al (1991) serially sectioned the substantia nigra pars compacta and 
used the Cavalieri and physical disector methods to measure the volume of the 
structure, as well as the number of pigmented and non-pigmented neurons, 
respectively. PD cases had a substantial mean 66% loss of pigmented neurons 
compared to controls and a mean 25% loss of non-pigmented neurons compared to 
control cases (Pakkenberg et al., 1991).  
The thalamic nuclei are also affected by Lewy body pathology and have been 
implicated in impaired physiological functions in PDD and DLB such as arousal, 
vigilance and cognition. The intralaminar thalamic nuclei have been investigated by 
serial sectioning of the thalamus to the emergence of the pulvinar, and the sampling 
at uniform intervals in DLB, PD and PDD cases (Brooks and Halliday, 2009). A 
significant reduction in neurons in the centrѐ-median/parafasicular, and volume in the 
paratenial, cucullar and central lateral nuclei, was found in DLB, PDD and PD cases, 
when compared to controls. A correlation between neuronal number and Lewy body 
burden was found in the centrѐ-median/parafasicular nucleus. No difference was 
found in neuron number in demented cases compared to non-demented cases, though 
cucullar nucleus losses were greater in hallucinating cases when compared to non-
hallucinating cases. 
The phenomenon of complex visual hallucinations has previously been suggested to 
be related to changes to the visual system in DLB (Taylor et al., 2011). Accordingly 
the afferent visual system has been examined in DLB patients using stereological 
protocol. A major component of the afferent visual system, the lateral geniculate 
nucleus (LGN), was investigated by serially sampling specimens and determining area 
using the Cavalieri method and estimating total neuronal number using the optical 
disector (Erskine et al., 2015). No differences in neuron number were found in 
hallucinating DLB cases when compared to non-hallucinating AD cases. However, 
non-hallucinating AD cases were shown to have significant neuronal loss and gliosis 
(Erskine et al., 2015).  
Respiratory disorders are often found in Lewy body disease and in other 
synucleinopathies such as multiple systems atrophy (Iranzo, 2007). In MSA, 
respiratory dysfunction is secondary to the autonomic dysfunction that marks the 
disorder, and typically subclinical in DLB (Iranzo, 2007). The pre-Bötzinger complex 
and the medullary raphe nuclei, which are thought to have a role in respiratory 
functioning respiration, have been investigated in MSA and Lewy body disease cases 
on the basis of this role in respiratory function (Presti et al., 2014). A significant 
reduction in neuron number was found in both regions in Lewy body disease and MSA 
cases, with a greater magnitude of reduction in MSA cases.  
 
6. Huntington’s disease 
Huntington’s disease (HD) is a motor disorder thought to result from a trinucleotide 
repeat expansion in the gene encoding huntingtin (Walker, 2007). Clinically, HD is  
marked by a variety of motor deficits including a distinct chorea, incoordination and 
slowed saccadic eye movements (Walker, 2007). In addition to motor symptoms, 
cognitive deficits are also frequently found, though they typically affect executive 
function rather than memory (Brandt et al., 1988). Neuropsychiatric symptoms are 
often common and HD patients have high rates of depression and suicide ideation (Di 
Maio et al., 1993). Pathologically, the striatum is atrophic and accordingly the existing 
staging scheme for determining the degree of HD neuropathological change is based 
upon the degree of neuronal loss and atrophy in the striatum (Vonsattel et al., 1985). 
However, post-mortem histology for the protein huntingtin or ubiquitin also reveals 
intranuclear and cytoplasmic inclusions in striatal and cortical neurons (Sieradzan et 
al., 1999) 
A focus of HD research has been the investigation of the striatum and basal ganglia, 
on the basis that deficits in these regions may underlie the well characterized motor 
deficits in this disorder (Vonsattel et al., 1985). Whilst three-dimensional stereological 
designs have not yet been used to study the striatum in HD, two-dimensional studies 
of neuronal density in single striatal sections have shown substantial reductions in HD 
when compared to control cases (Myers et al., 1991). Such approaches in other brain 
regions have also revealed cerebellar degeneration (Rub et al., 2013) and in the 
substantia nigra and pons (Rub et al., 2014). However, the cortex has also been 
implicated in HD, with two-dimensional densitometric studies showing reduced density 
of large neurons of layers three, five and six of the prefrontal cortex (Sotrel et al., 1991) 
and volumetric reductions in the neocortex (de la Monte et al., 1988). Considering the 
inherent problems of assuming that density acts as a proxy measure of total number, 
one study aimed to estimate neuronal number in the entire hemisphere of HD cases, 
using stereological methodology (Heinsen et al., 1994). The entire hemisphere was 
embedded and serially sectioned into 500µm-thick sections and stained with 
gallocyanin. Cortical and striatal total neuronal number were significantly reduced in 
HD compared to control cases.  
Although motor abnormalities are well described in HD, other clinical phenotypes are 
frequently encountered. Stereological techniques have proved useful in obtaining 
quantitative data in the investigation of topographical changes underlying divergent 
clinical phenotypes. Mood predominant phenotypes of HD are also well described (Di 
Maio et al., 1993) and the heterogeneity of the clinical presentation between motor- 
and mood-predominant phenotypes may reflect heterogeneous patterns of 
neuropathological change. On this basis, two studies have assessed both the primary 
motor and the anterior cingulate cortices. The anterior cingulate is thought to be 
strongly implicated in mood disorders (Ebert and Ebmeier, 1996). These studies (Thu 
et al., 2010, Kim et al., 2014) used well defined subregions of the primary motor and 
anterior cingulate cortices, which were sampled into a systematically random series of 
sections. The total neuronal number could not be determined due to the tissue for the 
entirety of the structures being unavailable. Therefore, the volume of each subregion 
was determined using the Cavalieri method and neuronal density was estimated using 
the optical disector. Significant neuronal loss was found in both the primary motor and 
the anterior cingulate cortices in HD cases compared to controls. However, neuronal 
number varied considerably in HD cases, with those classified as ‘motor-predominant’ 
showing more marked neuronal loss in the primary motor cortex and cases classified 
as ‘mood predominant’ showing greater neuronal loss in the anterior cingulate. 
Stereological analyses was also conducted on interneurons immunoreactive for the 
calcium-binding proteins parvalbumin, calretinin or calbindin. Selective significant 
reductions were found in calbindin immunoreactive neurons in motor-predominant HD 
cases, whereas significant reductions were found in parvalbumin, calretinin and 
calbindin immunoreactive neurons in mood-predominant HD cases. This study thus 
demonstrated the relationship between clinical features and neuropathological 
changes in the HD brain.   
 
7. Frontotemporal dementia 
Frontotemporal dementia (FTD) is clinically defined by behavioral changes, including 
changes in social conduct, disinhibition, loss of insight, apathy and emotional blunting 
(Faber, 1999). However, FTD is not heterogenous in terms of clinical features, with at 
least three subtypes (behavioral variant, semantic dementia and progressive nonfluent 
aphasia) recognized (Ghosh and Lippa, 2015). Overall, FTD is thought to be the third 
most common form of cortical dementia, accounting for approximately 5% of all 
dementias (Cairns et al., 2003). Neuropathologically, FTD is generally characterized 
by atrophy of the frontal and temporal lobes, which is apparent on macroscopic 
inspection (Cairns et al., 2007). FTD can also be divided into subtypes based on 
histological features of intracytoplasmic inclusions which are predominantly either tau-
positive Pick bodies (Delacourte et al., 1996), tau-negative ubiquitin-positive 
inclusions including TDP-43 (Seelaar et al., 2007, Arai et al., 2006) and inclusions that 
are tau- and TDP-43 negative, but positive for ubiquitin and FUS (Neumann et al., 
2009). Other subtypes based on features, such as those with p62-positive inclusions 
and those without significant histological features, are also occasionally encountered 
(Mackenzie et al., 2010). Cairns et al, 2003 charted the degree of atrophy and neuronal 
loss in these regions in FTD (Cairns et al., 2003). Due to the heterogeneity of 
neuropathological features of FTD, this study included cases from one subtype of FTD, 
which is characterized by the presence of ubiquitin-positive and tau-negative 
inclusions. Cortical thickness and neuronal density were reduced in FTD cases in the 
frontal, temporal and parietal cortices. Atrophy was hierarchical, with atrophy highest 
in frontal, followed by temporal, then parietal lobes. However, comparison with clinical 
information revealed heterogeneous clinical presentations, even in cases with similar 
pathological features. 
Abnormal eating behaviors and corresponding obesity are frequently encountered in 
FTD patients (Ahmed et al., 2014), prompting the assessment of morphometry and 
pathology in regions of the hypothalamus known to be involved in appetite regulation 
in cases with FTD (Piguet et al., 2011). All cases had behavioral variant FTD but with 
two pathological subtypes, those with Pick body and those with TDP-43 inclusions. 
The hypothalami were subdissected from coronal tissue slabs and serially sectioned, 
with sections taken at uniform intervals. The optical fractionator method was used to 
quantify cellular number on sections in the anterior and posterior regions. FTD cases 
were compared by their predominant pathology; those with TDP-43-predominant 
pathology had a significant loss of neurons in the posterior hypothalamus compared 
to controls and those with Pick body-predominant pathology. No changes in neuron 
number were found in the anterior hypothalamus across groups. Furthermore, no 
changes were found in neurons immunoreactive for proteins thought to be implicated 
in appetitive eating behaviors, such as orexin.  
 
8. AIDS 
AIDS is an acquired immunodeficiency virus that produces widespread and severe 
depletion of the CD4 antigen from lymphocytes, leading to compromised immune 
function and subsequent opportunistic infections (Dalgleish et al., 1984). The AIDS 
virus may enter the cerebrum through circulation of infected macrophages (Gartner, 
2000), or opportunistic infections that may compromise neurological functioning 
(Ketzler et al., 1990). A proportion of AIDS patients develop a dementia syndrome 
(Portegies, 1994). One study of 492 homosexual men in the USA showed that 15% 
had developed the AIDS dementia complex at the time of death (McArthur et al., 1993). 
The AIDS dementia complex is clinically marked by progressive dementia with 
cognitive components, such as executive deficits and learning dysfunction, as well as 
motor symptoms, including extrapyramidal symptoms and gait instability  (Brew and 
Chan, 2014). AIDS dementia complex is a dementing disorder secondary to a viral 
infection, rather than a neurodegenerative dementia like AD or DLB. However, the 
disorder warrants inclusion in the present review as, despite the often severe clinical 
dysfunction, many AIDS cases show minimal histopathological changes to the brain 
at autopsy (Navia et al., 1986). Therefore, researchers using stereological methods 
have been able to make major advances in the understanding of the disorder by 
investigating subtle morphometric changes that occur in the absence of severe 
degenerative pathological lesions.  
Three-dimensional designs using the Cavalieri method combined with point counting 
for the assessment of structural volume have revealed cerebral volume loss in AIDS 
cases, particularly in temporal and parietal regions, in the absence of changes to brain 
weight (Oster et al., 1993). The combination of volumetric analyses with optical density 
measures has also been employed in AIDS dementia complex research to estimate 
total neuronal number within structures. Two studies have shown no significant 
changes in neuron number in the CA1, CA2, CA3, CA4 and the stratum granulare of 
the dentate gyrus in the hippocampus in AIDS dementia complex (Korbo and West, 
2000, Sa et al., 2000). However, reductions in CA3 and CA4 neuronal volumes, as 
well as total hippocampal volume, have been reported in AIDS cases; however, such 
changes are not related to clinical variables (Sa et al., 2000). 
 9. Conclusions 
Stereological analysis has proved an important tool in the assessment of the major 
structural correlates of neurodegenerative dementing disorders. Despite limited 
sample size in many of the studies, largely due to the strict sampling protocol and 
labor- and time-consuming preparatory and analytical procedures, these studies have 
provided important mechanistic insights into the relationship between the pathological 
changes that define the clinical features in the dementias. Stereological procedures 
are particularly useful in dementing disorders that do not possess overt pathological 
lesions or histological features, such as AIDS dementia complex and certain subtypes 
of FTD (Cairns et al., 2007, Navia et al., 1986). Nevertheless, the studies reviewed 
here have, in large part, focussed on cellular morphology, specifically soma number 
or volume, with other structures, such as length of blood vessels and dendritic arbor, 
and volume of amyloid plaque pathology, meaning many stereological applications 
remain under-utilized. However, increased awareness of the importance and benefits 
of correct unbiased sampling and analytical protocol in a brain bank environment, as 
well as advances in analytical technology, may encourage future dementia 
researchers to incorporate novel stereological designs in pathology research. 
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